Bone Biologics Corp
BBLG
Company Profile
Business description
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Contact
2 Burlington Woods Drive
Suite 100
BurlingtonMA01803
USAT: +1 781 552-4452
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,061.20 | 20.50 | -0.23% |
CAC 40 | 7,853.59 | 1.02 | -0.01% |
DAX 40 | 23,639.41 | 35.12 | -0.15% |
Dow JONES (US) | 46,287.23 | 144.81 | 0.31% |
FTSE 100 | 9,216.67 | 11.44 | -0.12% |
HKSE | 26,545.10 | 0.25 | 0.00% |
NASDAQ | 22,571.17 | 100.45 | 0.45% |
Nikkei 225 | 45,045.81 | 257.62 | -0.57% |
NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
S&P 500 | 6,652.43 | 20.47 | 0.31% |
S&P/ASX 200 | 8,773.50 | 18.70 | -0.21% |
SSE Composite Index | 3,820.09 | 11.57 | -0.30% |